Search Within

Andrew D Seidman

  1. "Gynecologic Medicine Service"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (6)
Groups
  1. Breast Medicine Service (18)
  2. Department of Medicine (18)
  3. Gynecologic Medicine Service (18)
  4. Solid Tumor Oncology Division (18)
  5. Survivorship Research (18)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (11)

More Groups

People
  1. Clifford Hudis (16)
  2. Gabriella D'Andrea-Carlino (12)
  3. Larry Norton (11)
  4. Monica Fornier (10)
  5. Steven Sugarman (10)
  6. Tiffany Troso-Sandoval (10)

More People

Years
  1. 2021 (1)
  2. 2018 (2)
  3. 2016 (1)
  4. 2014 (2)
  5. 2013 (1)
  6. 2012 (1)

More Years

Publications
  1. Journal of Clinical Oncology (7)
  2. Breast Cancer Research and Treatment (3)
  3. Cancer Research (3)
  4. Clinical Breast Cancer (3)
  5. Annals of Oncology (1)
  6. EJC Supplements (1)
Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (3)
  3. Elsevier Inc. (3)
  4. Springer (3)
  5. Oxford University Press (1)
  6. Pergamon-Elsevier Science Ltd (1)

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care
    Meeting Abstract

    Traina, T. A.; Kantoff, P. W.; Matasar, M. J.; Dunn, L.; Friedman, C. F.; Voss, M. H.; Seidman, A. D.; Cahlon, O.; Zauderer, M. G.; Manship, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage human epidermal growth factor receptor 2–negative breast cancer
    Journal Article

    Cadoo, K. A.; Kaufman, P. A.; Seidman, A. D.; Chang, C.; Xing, D.; Traina, T. A.
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel and dasatinib in metastatic breast cancer
    Journal Article

    Morris, P. G.; Rota, S.; Cadoo, K.; Zamora, S.; Patil, S.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; more...
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage breast cancer
    Meeting Abstract

    Cadoo, K.; Kaufman, P. A.; Hudis, C.; Chang, C.; Berrak, E.; Song, J.; Seidman, A. D.; Traina, T. A.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC)
    Meeting Abstract

    Traina, T. A.; Kaufman, P. A.; Cadoo, K. A.; Hudis, C. A.; Chang, C.; Berrak, E.; Song, J.; Cox, D.; Seidman, A. D.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Morris, P. G.; Lake, D. E.; D'Andrea, G. M.; Dickler, M. N.; Gilewski, T. A.; Dang, C. T.; McArthur, H. L.; Bromberg, J. F.; Goldfarb, S. B.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: Combined analysis of calgb 9342 and 9840
    Journal Article

    Lichtman, S. M.; Hurria, A.; Cirrincione, C. T.; Seidman, A. D.; Winer, E.; Hudis, C.; Cohen, H. J.; Muss, H. B.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Journal Article

    Drullinsky, P.; Sugarman, S. M.; Fornier, M. N.; D'Andrea, G.; Gilewski, T.; Lake, D.; Traina, T.; Wasserheit-Lieblich, C.; Sklarin, N.; Atieh-Graham, D.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer
    Meeting Abstract

    Drullinsky, P.; Fornier, M. N.; Sugarman, S.; D'Andrea, G.; Troso-Sandoval, T.; Seidman, A. D.; Yuan, J.; Patil, S.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save